MedTrace Logo

LA PrEP Impact and Cost-effectiveness (TEAMS)

NCT05774548 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10720

Last updated 2026-03-18

No results posted yet for this study

Summary

This study will have three components:

1. Discrete choice experiments
2. Analysis of routine service data
3. Impact and cost-effectiveness analyses using results from 1 and 2

Conditions

Interventions

OTHER

In-depth interviews (IDI)

In-depth interviews (IDI) 20 MSM,20 TGW, current, previous PrEP users will assess which attributes are relevant each population. Posters will be used to recruit for IDIs. Self-reported HIV-negative who either report interest in current or past PrEP use will be eligible to participate in IDI. IDI will be conducted by a study by in-person, on-line interviews.

OTHER

Focus group discussion (FGD)

Focus group discussion (FGD) will discuss a interested information from IDIs. IDIs will be informed, invited to a FGD. FGD recruit 6-10 IDI. 10 random number will be generated using statistical if more 10 individuals show interest in participating in a FGD. If there are less than 6 accepted participants for a FGD, the backup list or new participant will be invited. Study will perform FGD by in-person, on-line conference. Data obtained during a process will be used to create a list of attributes for each population, their levels to include in the choice tasks, ensuring that a choices are plausible, exchangeable.

Sponsors & Collaborators

  • Erasmus Medical Center

    collaborator OTHER

  • Institute of HIV Research and Innovation Foundation, Thailand

    lead OTHER

Principal Investigators

  • Nittaya Phanuphak, MD,PhD. · INSTITUTE OF HIV RESEARCH AND INNOVATION FOUNDATION

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-15
Primary Completion
2026-12-15
Completion
2028-12-30

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05774548 on ClinicalTrials.gov